A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Inclusion Criteria : * Participant must be ≥18 years of age at the time of signing the informed consent. * Participants who have histological or cytologically confirmed adenocarcinoma of the pancreas. * Participants with an initial diagnosis of progressive metastatic disease * Participants with a confirmed diagnosis of metastatic adenocarcinoma of the pancreas with disease progression following gemcitabine-based therapy. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 * Adequate haematological parameters * Adequate hepatic function * Adequate renal function * Adequate coagulation * No clinically significant abnormalities in urinalysis results * Electrocardiogram (ECG) without any clinically significant findings * Participants known to be infected with controlled human immunodeficiency virus (HIV) * Male and female participants: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies * Capable of giving signed informed consent Exclusion Criteria : * Have only localised advanced disease. * History of any second malignancy in the last 2 years. * Known history of central nervous system metastases * Clinically significant gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, diarrhoea \>Grade 1, malabsorption syndrome, ulcerative colitis, inflammatory bowel disease or partial bowel obstruction. * Concurrent illnesses that would be a relative contraindication to trial participation such as active cardiac or liver disease * Active infection or an unexplained fever \>38.5°C on the first scheduled day of dosing * Neuroendocrine tumour (carcinoid, islet cell) or acinar pancreatic carcinoma * History of interstitial lung disease, history of slowly progressive dyspnoea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies. * Exposure to a non-liposomal irinotecan or SN-38 based regimen within 4 weeks prior to randomisation, or exposure to Onivyde or other irinotecan based liposomal products within 6 weeks prior to randomisation * Major surgery, other than diagnostic surgery, within 4 weeks prior to randomisation * Participants who have received a live vaccine within 4 weeks prior to randomisation. * Use of strong CYP3A inhibitors or inducers, or strong inhibitors of UGT1A1. * Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to study intervention on Cycle 1 Day 1 * Known low or absent dihydropyrimidine dehydrogenase (DPD) activity. * Homozygous for the UGT1A1\*28 allele. * Known hypersensitivity to any of the components of Onivyde injection, other liposomal products, or any components of 5-FU, or LV * Presence of any contraindications outlined in the Contraindications or Warnings and Precautions sections of the IB for Onivyde, or in the prescribing information for 5-FU or LV. * Participants who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening * Any other medical or social condition deemed by the investigator to be likely to interfere with a participant's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results